Potential Benefits of the BioFire Joint Infection Panel2
Compared to the standard of care, the BioFire JI Panel may provide a faster and more straightforward method of diagnosing joint infections. Rapid results may help inform surgical decision making and optimal antibiotic selection. Because the BioFire JI Panel accurately detects some organisms that are often missed by culture, it is likely to increase the diagnostic yield when used in conjunction with standard-of-care methods. The inclusion of antibiotic resistance genes can help healthcare providers optimize therapy sooner and avoid unnecessary antibiotic prescriptions.
Since 2018, prospective clinical evaluations of the BioFire JI Panel have been conducted worldwide. These evaluations have shown a high sensitivity and specificity for target organisms and antimicrobial resistance genes. Overall, the BioFire JI Panel claims about 91.7% sensitivity and 99.8% specificity.3
With a panel menu of 39 targets, the BioFire JI Panel aims to accompany culture-based diagnostics for joint infections. Results are intended to be used in conjunction with other existing data and not as the sole basis for diagnosis and treatment.